Jun 16, 2026
17 MIN READ

Do You Lose More Weight with Wegovy or Mounjaro?

Wegovy and Mounjaro produce different weight loss outcomes depending on your body's response to GLP-1 or dual-action peptide therapy. Understanding the clinical data helps you choose the right medication for your weight management goals.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 16, 2026
17 MIN READ

do you lose more weight with wegovy or mounjaro? — PlexusDx GLP-1 education

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (Wegovy) and tirzepatide (Mounjaro) both reduce appetite and support weight loss, but they work through different mechanisms and deliver distinct results in clinical trials. PlexusDx offers compounded versions of both medications at transparent, dose-independent pricing, allowing you to access the therapy that matches your metabolic needs without breaking your budget.

How Semaglutide and Tirzepatide Differ in Mechanism

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that signals satiety to your brain and slows stomach emptying. This single-action approach has proven effective for millions of people managing weight. Tirzepatide, by contrast, activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously, creating a dual-action effect that engages additional appetite-suppression pathways in your central nervous system.

The dual-receptor activation in tirzepatide may trigger stronger metabolic adjustments in individuals whose genetic makeup favors GIP-pathway responsiveness. Your body's unique peptide-receptor landscape determines whether a single-action or dual-action medication delivers superior results—a distinction that genetic testing can reveal before you commit to treatment.

Clinical Trial Weight Loss Outcomes: Semaglutide vs Tirzepatide

The STEP trials demonstrated that semaglutide at maintenance doses (2.4 mg weekly) produced average weight loss of 10% to 18% of baseline body weight over 68 weeks, depending on the study population and adherence. Participants typically lost 10–15 pounds in the first month and continued steady decline over the treatment duration. Results varied based on individual factors including starting weight, metabolic rate, and adherence to dose escalation schedules.

The SURMOUNT trials showed tirzepatide at its highest approved dose (15 mg weekly) achieved average weight loss of 20% to 22% of baseline body weight over 72 weeks—a clinically meaningful difference compared to semaglutide monotherapy. Some participants lost over 50 pounds, though outcomes remained highly individual. The superior tirzepatide results likely reflect the dual-receptor mechanism engaging multiple appetite-regulation and metabolic-control pathways simultaneously.

Direct head-to-head comparisons remain limited in published literature, but the available data suggests tirzepatide produces steeper and more consistent weight loss trajectories in most populations. However, 'most' does not mean 'all'—individual responses depend on your genetic predispositions, baseline insulin sensitivity, and GIP-receptor expression levels.

Individual Response Variability and Genetic Factors

Not everyone responds identically to semaglutide or tirzepatide, even at equivalent doses. Some individuals experience profound appetite suppression and rapid weight loss within weeks, while others see gradual progress or plateau at lower body-weight reductions. This variability is partly genetic: your inherited variations in genes like GLP1R (rs6923761), GIPR (rs1800437), and MC4R (rs17782313) influence how effectively your receptors bind to and signal from these peptides.

The PlexusDx Precision Peptide Genetic Test analyzes 14 distinct metabolic pathways and 49 peptide-related variants to map your peptide-response profile across 150+ genetic insights. Knowing whether your GLP-1 receptors are optimally expressed or your GIP-pathway sensitivity is elevated allows you and your provider to select semaglutide or tirzepatide—or even the dual-compound GLP-Squared formulation—with evidence-based confidence rather than trial-and-error.

Cost Comparison and Access Through PlexusDx

Branded Wegovy (semaglutide) typically costs $900–$1,400 per month without insurance, while branded Mounjaro (tirzepatide) ranges from $1,000–$1,500 monthly at retail prices. PlexusDx compounded semaglutide injection starts at $149 per month and compounded tirzepatide injection starts at $249 per month—both available without insurance, no membership fee, and HSA/FSA eligible. Your dose may need to go up. Your price won't.

For patients preferring oral formulations, PlexusDx offers oral semaglutide starting at $249 per month and oral tirzepatide starting at $279 per month. Those curious about dual-action therapy without committing to tirzepatide alone can explore the GLP-Squared injection (dual semaglutide and tirzepatide compound) starting at $249 per month. All medications source from licensed 503A compounding pharmacies, serving all 50 states with the same quality standards and potency testing as brand-name products.

Choosing Between Wegovy and Mounjaro for Your Situation

If you have mild insulin resistance, stable blood sugar, or a family history of strong GLP-1 responsiveness, semaglutide may deliver excellent results at lower cost and potentially fewer side effects. Semaglutide carries a simpler mechanism, longer clinical safety history, and a gentler tolerance curve for many first-time users. It remains the right choice for individuals who prefer simplicity or who experienced GIP-pathway side effects in other contexts.

Tirzepatide typically suits individuals with moderate-to-severe insulin resistance, prediabetic glucose patterns, or prior suboptimal response to GLP-1-only therapy. The dual-action profile addresses metabolic dysfunction more comprehensively and often produces faster, larger weight reductions in head-to-head scenarios. PlexusDx Precision Peptide Genetic Testing ($99 after your first month on treatment) clarifies whether your genetic architecture favors one peptide pathway over another, removing guesswork and supporting personalized therapy selection.

Neither choice is universally 'better'—better means better for you. Your genetics, current metabolic health, weight-loss goals, side-effect tolerance, and budget all factor into the decision. PlexusDx providers review your baseline labs, health history, and (optionally) genetic insights to recommend semaglutide, tirzepatide, or even a dual-compound protocol tailored to your individual profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will I lose more weight on tirzepatide (Mounjaro) than semaglutide (Wegovy)?

Clinical trial data shows tirzepatide typically produces 20–22% weight loss versus 10–18% for semaglutide, but individual results vary significantly based on your genetics, starting weight, and adherence. Some people achieve their goals on semaglutide alone, while others require tirzepatide's dual-action effect. PlexusDx genetic testing can help identify which pathway your body favors.

How long does it take to see weight loss results on Wegovy or Mounjaro?

Most people notice appetite suppression within 3–7 days and measurable weight loss within 2–4 weeks at therapeutic doses. Semaglutide typically shows steady monthly progress, while tirzepatide often produces faster initial losses. Results depend on your baseline metabolism, dose, and how consistently you follow the dose-escalation schedule.

Can I switch from Wegovy to Mounjaro or vice versa?

Yes, switching is medically safe and common. Many patients trial semaglutide first, then transition to tirzepatide if results plateau or if they want to explore dual-action therapy. PlexusDx providers can manage the transition, ensuring proper washout timing and dose conversion to minimize side effects and maintain momentum.

What are the side effects of semaglutide versus tirzepatide?

Both medications share common GLP-1 side effects: nausea, vomiting, diarrhea, and constipation, typically worse during dose escalation and improving over time. Tirzepatide may cause additional nausea in some users due to GIP-pathway activation, though most adjust within 2–3 weeks. Serious adverse events (pancreatitis, thyroid concerns) are rare in both. Always report persistent symptoms to your provider.

How does PlexusDx pricing compare to brand-name Wegovy and Mounjaro?

PlexusDx compounded semaglutide starts at $149/month and tirzepatide at $249/month—roughly 75–80% less than brand-name equivalents ($900–$1,500/month). All medications are 503A-compounded, HSA/FSA eligible, no insurance required, and available nationwide. Your dose may go up; your price won't, thanks to flat monthly pricing.

What is the PlexusDx Precision Peptide Genetic Test and how does it help?

This test ($99 after your first treatment month) analyzes 14 metabolic pathways and 49 peptide-related genetic variants—including GLP1R and GIPR—to reveal which appetite and metabolism genes you carry. The insights guide your provider in selecting semaglutide, tirzepatide, or dual-compound therapy that aligns with your unique genetic predispositions, improving personalization and response likelihood.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves